Contact CFFC

Oct

Clinical Trial Alerts – October 2020

Cystic Fibrosis Foundation issued the following clinical trial alerts in October.

October 15, 2020

Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis

Status: Completed with Results

Description: This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.

Age: 6 Years to 11 Years

Mutation: Two Copies F508del or One Copy F508del

Fev1% Predicted: 40% or greater

Number of Visits: 9

Length of Participation: 32 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03691779

Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis and an NTM infection in the lungs

Status: Completed with Results

Description: This study evaluated the effectiveness of inhaled molgramostim (Molgradex), a drug intended to treat nontuberculous mycobacterial (NTM) infections in the lungs of people with CF.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 30% or greater

Number of Visits: 19

Length of Participation: 72 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03597347


Comments are closed.